Trial · NCT04836559
Participant flow88
How many started, completed or left each group, period by period.
21 to 40 of 88
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double Blind Period (Day 1 to Day 85) | Subjects Treated With EIAED | OLE: Cohort 1: Placebo Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Treated With EIAED | OLE: Cohort 1: JNJ-40411813 Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Treated With EIAED | OLE: Cohort 2: Placebo Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Treated With EIAED | OLE: Cohort 2: JNJ-40411813 Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Not Treated With EIAED | DB: Cohort 1: Placebo | 9 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Not Treated With EIAED | DB: Cohort 1: JNJ-40411813 | 18 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Not Treated With EIAED | DB: Cohort 2: Placebo | 3 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Not Treated With EIAED | DB: Cohort 2: JNJ-40411813 | 17 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Not Treated With EIAED | OLE: Cohort 1: Placebo Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Not Treated With EIAED | OLE: Cohort 1: JNJ-40411813 Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Not Treated With EIAED | OLE: Cohort 2: Placebo Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | Subjects Not Treated With EIAED | OLE: Cohort 2: JNJ-40411813 Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | COMPLETED | DB: Cohort 1: Placebo | 18 | |
| Double Blind Period (Day 1 to Day 85) | COMPLETED | DB: Cohort 1: JNJ-40411813 | 35 | |
| Double Blind Period (Day 1 to Day 85) | COMPLETED | DB: Cohort 2: Placebo | 7 | |
| Double Blind Period (Day 1 to Day 85) | COMPLETED | DB: Cohort 2: JNJ-40411813 | 36 | |
| Double Blind Period (Day 1 to Day 85) | COMPLETED | OLE: Cohort 1: Placebo Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | COMPLETED | OLE: Cohort 1: JNJ-40411813 Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | COMPLETED | OLE: Cohort 2: Placebo Followed by JNJ-40411813 | 0 | |
| Double Blind Period (Day 1 to Day 85) | COMPLETED | OLE: Cohort 2: JNJ-40411813 Followed by JNJ-40411813 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04836559/flow?page=2